Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Plasmodium berghei | glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase, putative | Starlite/ChEMBL | No references |
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | glucosamine-6-phosphate isomerase, putative | 0.0123 | 0.5913 | 0.5 |
Trypanosoma cruzi | glucose-6-phosphate 1-dehydrogenase, putative | 0.0113 | 0.5204 | 0.5 |
Treponema pallidum | glucose-6-phosphate 1-dehydrogenase | 0.0113 | 0.5204 | 0.5 |
Mycobacterium tuberculosis | Probable glucose-6-phosphate 1-dehydrogenase Zwf2 (G6PD) | 0.0039 | 0 | 0.5 |
Leishmania major | glucose-6-phosphate 1-dehydrogenase, putative | 0.0113 | 0.5204 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Trichomonas vaginalis | glucosamine-6-phosphate isomerase, putative | 0.0123 | 0.5913 | 0.5 |
Echinococcus granulosus | muscleblind protein | 0.018 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 1 | 1 |
Schistosoma mansoni | glucose-6-phosphate 1-dehydrogenase | 0.0113 | 0.5204 | 0.5 |
Toxoplasma gondii | glucose-6-phosphate 1-dehydrogenase | 0.0123 | 0.5913 | 1 |
Plasmodium vivax | glucose-6-phosphate 1-dehydrogenase, putative | 0.0123 | 0.5913 | 0.5 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 1 | 1 |
Plasmodium falciparum | glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | 0.0123 | 0.5913 | 1 |
Giardia lamblia | Glucose-6-phosphate 1-dehydrogenase | 0.0123 | 0.5913 | 0.5 |
Mycobacterium ulcerans | glucose-6-phosphate 1-dehydrogenase | 0.0113 | 0.5204 | 1 |
Chlamydia trachomatis | glucose-6-phosphate 1-dehydrogenase | 0.0113 | 0.5204 | 0.5 |
Trichomonas vaginalis | 6-phosphogluconolactonase, putative | 0.0123 | 0.5913 | 0.5 |
Trypanosoma brucei | glucose-6-phosphate 1-dehydrogenase | 0.0113 | 0.5204 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 11.8 uM | PUBCHEM_BIOASSAY: Dose Response confirmation of uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase via a fluorescence intensity assay. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
IC50 (functional) | > 80 uM | PUBCHEM_BIOASSAY: Human Glucose-6-Phosphate Dehydrogenase Dose Response Selectivity Assay for Inhibitors of Plasmodium falciparum Glucose-6-Phosphate Dehydrogenase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
IC50 (functional) | > 80 uM | PUBCHEM_BIOASSAY: Dose Response orthogonal assay utilizing the direct end-point detection of NADPH for uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
IC50 (functional) | > 80 uM | PUBCHEM_BIOASSAY: Dose Response orthogonal kinetic assay utilizing the direct detection of NADPH for uHTS small molecule inhibitors of Plasmodium falciparum Glucose-6-phosphate dehydrogenase. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504690, AID504696] | ChEMBL. | No reference |
Potency (functional) | 7.3753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | 17.7828 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.